Floatz logo

OFRANERGENE OBADENOVEC

Recurrent Platinum Resistant Ovarian Cancer

Vascular Biogenics Ltd. operating as VBL Therapeuticsgene_therapyPhase 3Dormant
B
61/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
46/ 100
Competitive Position
95/ 100

Competitive context

525 Active assets in the Recurrent Platinum Resistant Ovarian Cancer cohort.

Asset / SponsorPhaseRating
TIL
Inge Marie Svane
Phase 2BB
Tisotumab Vedotin
Seagen Inc.
Phase 2BB
Olaparib
Shandong University
Phase 4BB
Irinotecan
ARCAGY/ GINECO GROUP
Phase 4BB
Carboplatin
Fudan University
Phase 4BB

View all 50 →

Same molecule, other indications

OFRANERGENE OBADENOVEC is also rated in:

glioblastomaDormant
B
Indicative ·
56 / 100
View asset →
Colorectal Cancer With Hepatic MetastasesDormant
CCC
Indicative ·
53 / 100
View asset →
colorectal neoplasmDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →